Clinical Trial

Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)

Study acronym: KIDCARES10
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess efficacy, safety and pharmacokinetics of Kedrion Immunoglobulin 10% (KIg10) in pediatric patients with Primary Immunodeficiency Disease (PID).
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-04-30 -> 2026-12 2026-05-30
minor Completion pushed: 2026-10-30 -> 2027-05 2026-05-30
Trial Details
NCT Number NCT04944979
Lead Sponsor Kedrion S.p.A.
Conditions Primary Immunodeficiency Disease
Enrollment 30 participants
Start Date 2021-03-31
Primary Completion 2026-12 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-05-29